The Indian Pharmaceutical Market (IPM) registered a value growth of 11.0 per cent with unit growth of 1.3 per cent for the month of February 2026, indicating continued momentum across therapy segments. Most therapy areas recorded positive value growth, with several major therapies also demonstrating healthy expansion in unit volumes.
According to Sheetal Sapale, Vice President – Commercial, Pharmarack Technologies, the cardiac segment continued to dominate the IPM with sales of Rs 2,937 crore, accounting for 14 per cent contribution to the market during February 2026. The therapy posted a value growth of 14.8 per cent supported by unit growth of 5.8 per cent.
The gastrointestinal segment recorded sales of Rs 2,345 crore, contributing 11 per cent to the market. However, the segment registered value growth of 4.5 per cent while unit growth declined by 6.7 per cent.
The anti-infectives segment reported sales of Rs 2,284 crore with 11 per cent contribution to the IPM. The therapy posted value growth of 7.6 per cent, though unit growth declined by 2.6 per cent during the month.
The anti-diabetic segment, one of the key chronic therapy areas, recorded sales of Rs 1,982 crore, contributing 10 per cent to the IPM. The therapy registered value growth of 15.5 per cent along with unit growth of 4.4 per cent, reflecting sustained demand for diabetes management therapies.
The vitamins, minerals and nutrients segment posted sales of Rs 1,831 crore, accounting for 9 per cent contribution to the market. The therapy reported value growth of 13.3 per cent with unit growth of 5.3 per cent.
Among all therapy segments, vaccines emerged as the fastest growing category during the month. The segment reported sales of Rs 220 crore, contributing 1 per cent to the IPM, and recorded the highest value growth of 30.1 per cent along with a sharp unit growth of 44.0 per cent, indicating strong demand and uptake.
Overall, the February 2026 performance highlights steady growth in the Indian pharmaceutical market, with chronic therapies continuing to drive value expansion while vaccines and specialty therapies show strong growth momentum.
